Non-Alcoholic Steatohepatitis (NASH) Market Share, Trends, Growth, Size & Forecast 2023-2028

IMARC Group, a leading market research company, has recently released a report titled "Non-Alcoholic Steatohepatitis (NASH) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" The study provides a detailed analysis of the industry, including the non-alcoholic steatohepatitis (NASH) market size, share, trends and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

How big is the Non-Alcoholic Steatohepatitis (NASH) Market?

The global non-alcoholic steatohepatitis (NASH) market size reached US$ 1.21 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 5.55 Billion by 2028, exhibiting a growth rate (CAGR) of 27.70% during 2023-2028.

What is Non-Alcoholic Steatohepatitis (NASH)?

NASH, or non-alcoholic steatohepatitis, is a liver condition that occurs due to factors such as insulin resistance, overweight, and metabolic syndrome. Common symptoms include fatigue, weakness, weight loss, jaundice, itchy skin, spider veins, enlarged liver, lack of concentration, fluid accumulation, and abdominal discomfort. Diagnosis of NASH involves various methods such as physical examination, blood tests, liver biopsy, MRI, ultrasound, and CT scan. Treatment options for NASH include medication, liver transplant, and lifestyle changes, including exercise and adopting a healthy diet. The goal of these treatments is to reduce liver fat, improve liver function, minimize inflammation, and manage obesity and high blood pressure, among other factors.

Request for a sample copy of this report: https://www.imarcgroup.com/non-alcoholic-steatohepatitis-market/requestsample

What are the growth prospects and trends in the non-alcoholic steatohepatitis (NASH) industry?

The non-alcoholic steatohepatitis (NASH) market is driven by several factors. Firstly, there is an increasing prevalence of this condition due to genetics, sedentary lifestyles, and unhealthy eating habits. Patients are adopting advanced treatment procedures to alleviate symptoms, improve lifespan, and enhance overall well-being, which is contributing to market growth. Additionally, there is growing awareness among the public about the importance of early diagnosis and therapies to reduce healthcare expenses, avoid liver transplants, and prevent complications such as high blood pressure, cardiovascular diseases, cancer, and cirrhosis. The demand for non-invasive imaging techniques like MRI and TE is also on the rise, as they provide patient comfort, better compliance, reduced complications, and improved clinical outcomes. Furthermore, the integration of artificial intelligence in healthcare for personalized treatments, accurate diagnosis, and disease progression prediction is driving market growth. Government policies supporting access to high-quality treatment and advanced therapeutics are also playing a role in boosting the NASH market. These factors are expected to contribute to the growth of the NASH market in the coming years.

Browse Full Report with Table of Contents : https://www.imarcgroup.com/non-alcoholic-steatohepatitis-market

What is included in market segmentation?

The report has segmented the market into the following categories:

Drug Type Insights:

Vitamin E and Pioglitazone
Ocaliva
Elafibranor
Selonsertib
Cenicriviroc
Others

Disease Cause Insights:

Hypertension
Heart Disease
High Blood Lipid
Type 2 Diabetes
Obesity

Sales Channel Insights:

Hospital Pharmacy
Online Providers
Retail Pharmacy

End User Insights:

Hospitals
Clinics
Homecare Settings

Market Breakup by Region:

North America (United States, Canada)
Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa

Who are the key players operating in the industry?

The report covers the major market players including:

Algernon Pharmaceuticals
Galmed Pharmaceuticals Ltd
Intercept Pharmaceuticals Inc.
Zydus Lifesciences Limited

Ask Analyst for Sample Report: https://www.imarcgroup.com/request?type=report&id=7397&flag=C

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Contact US
IMARC Group
Email: sales@imarcgroup.com
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Address: 134 N 4th St. Brooklyn, NY 11249, USA
Follow us on Twitter: @imarcglobal

About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.